Identity
Mazdutide is a dual GLP-1/glucagon receptor agonist.
Source-specific finding, not full clinical sign-off.
Peptide library
Mazdutide
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Positive phase III weight-loss evidence now extends the original phase II snapshot. Chinese treatment-policy results and U.S. hypothetical-estimand results answer different questions; the latter’s highest dose had substantial adverse-event discontinuation. Neither is a direct comparison with other active drugs.
About this assessment
Selected full-text methods/results or correction sections assessed.
This assessment covers selected sources and sections. It is not a systematic review, formal risk-of-bias score, or clinician sign-off.
Editorial assessment · 2026-09-07
Source 1 · pubmed.ncbi.nlm.nih.gov
Who was studied
GLORY-1: 610 Chinese adults with obesity or overweight plus a weight-related condition; separately a U.S. phase II trial randomized 179 adults without type 2 diabetes.
What the sources found
GLORY-1 randomized 610 Chinese adults. At week 32, treatment-policy weight changes were −10.09% and −12.55% for the two mazdutide groups versus +0.45% with placebo. These positive phase III results extend the earlier phase II evidence but do not compare mazdutide directly with another active medicine.
Phase III GLORY-1; treatment-policy estimand; China-specific population.
Regulatory scope
Current authorization must be checked for the exact product, indication and jurisdiction.
What remains unknown
The newer U.S. trial used an efficacy (hypothetical) estimand, whereas GLORY-1 reported treatment-policy estimates; their percentages are not interchangeable. The U.S. highest-dose group had 20% treatment discontinuation due to adverse events. Full protocols, longer-term outcomes and the exact marketed-product label still require assessment.
How it works
Mazdutide is a dual GLP-1/glucagon receptor agonist.
Read the source-specific findings; biological activity is not equivalent to a clinical treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Common events included diarrhea, nausea and upper respiratory infection.
Source-specific finding, not full clinical sign-off.
Contraindications
- Full clinical contraindication and interaction assessment remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Source 1 · pubmed.ncbi.nlm.nih.gov
Claim-by-claim evidence
Benefits
At 24 weeks the highest-dose group had −11.3% mean weight change versus +1.0% with placebo. Later evidence and authorization need separate checking.
Source-specific finding, not full clinical sign-off.
Adverseeffects
Common events included diarrhea, nausea and upper respiratory infection.
Source-specific finding, not full clinical sign-off.
Findings
GLORY-1 randomized 610 Chinese adults. At week 32, treatment-policy weight changes were −10.09% and −12.55% for the two mazdutide groups versus +0.45% with placebo. These positive phase III results extend the earlier phase II evidence but do not compare mazdutide directly with another active medicine.
Phase III GLORY-1; treatment-policy estimand; China-specific population.
Benefits
A 179-person U.S. phase II trial also found weight loss, but 20% of the highest-dose group stopped treatment because of adverse events. Dose-specific tolerability and trial estimands matter when interpreting headline percentages.
U.S. phase II study, indexed abstract reviewed; hypothetical efficacy estimand.
References
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. 2023.
PMID: 38092790
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. 2025.
PMID: 40421736
Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. 2026.
PMID: 42628555
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.